Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock

This study has been completed.

Sponsor:

Collaborator:

Eli Lilly and Company

Information provided by:

Charles University, Czech Republic

ClinicalTrials.gov Identifier:

NCT00420030

First received: January 8, 2007

Last updated: June 22, 2009

Last verified: June 2009

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2009
Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

No publications provided by Charles University, Czech Republic

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Tousek P, Rokyta R, Tesarova J, Pudil R, Belohlavek J, Stasek J, Rohac F, Widimsky P. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study. Acute Card Care. 2011 Sep;13(3):116-22. Epub 2011 Apr 28.

To Top